Institution
Victor Chang Cardiac Research Institute
Nonprofit•Sydney, New South Wales, Australia•
About: Victor Chang Cardiac Research Institute is a nonprofit organization based out in Sydney, New South Wales, Australia. It is known for research contribution in the topics: Mechanosensitive channels & Heart failure. The organization has 708 authors who have published 1599 publications receiving 70035 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, the authors integrate drug-target data with candidate gene prediction systems to identify novel phenotypes which may benefit from current therapeutics, which can save valuable time and money spent on preclinical studies and phase I clinical trials.
Abstract: Human genome sequencing has enabled the association of phenotypes with genetic loci, but our ability to effectively translate this data to the clinic has not kept pace. Over the past 60 years, pharmaceutical companies have successfully demonstrated the safety and efficacy of over 1,200 novel therapeutic drugs via costly clinical studies. While this process must continue, better use can be made of the existing valuable data. In silico tools such as candidate gene prediction systems allow rapid identification of disease genes by identifying the most probable candidate genes linked to genetic markers of the disease or phenotype under investigation. Integration of drug-target data with candidate gene prediction systems can identify novel phenotypes which may benefit from current therapeutics. Such a drug repositioning tool can save valuable time and money spent on preclinical studies and phase I clinical trials.
33 citations
TL;DR: Conformational changes upon conjugation of nitric oxide and glutathione are generally small and often accompanied by a local increase in protein disorder, which may increase the timeframe of signalling.
33 citations
TL;DR: Current evidence discourages any attempt to discontinue RAAS inhibitors or beta-blockers in patients with stable HF, regardless of clinical and/or echocardiographic status.
33 citations
TL;DR: Five patients implanted with continuous flow centrifugal left ventricular assist devices who displayed clinical, hemodynamic, and laboratory features of intrapump thrombosis may support the use of intravenous thrombolytics for suspected pump thrombus in these newer generation devices.
Abstract: The current recommended anticoagulation regimen during continuous flow centrifugal left ventricular device support is a combination of antiplatelet therapy as well as oral anticoagulation Despite this, pump thrombosis occurs in rare situations We report the risk factors and nonsurgical management and outcomes of five patients implanted with continuous flow centrifugal left ventricular assist devices who displayed clinical, hemodynamic, and laboratory features of intrapump thrombosis This information may support the use of intravenous thrombolytics for suspected pump thrombus in these newer generation devices
33 citations
TL;DR: An isotropic cell stretch system (IsoStretcher) that uses a rotational swivel mechanism that translates into a radial displacement of hooks attached to small circular silicone membranes that provides a useful versatile tool for mechanobiology.
33 citations
Authors
Showing all 728 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Bruce D. Walker | 155 | 779 | 86020 |
| Stefanie Dimmeler | 147 | 574 | 81658 |
| Matthias W. Hentze | 110 | 319 | 41879 |
| Roland Stocker | 92 | 331 | 34364 |
| Richard P. Harvey | 83 | 403 | 27060 |
| Michael F. O'Rourke | 81 | 451 | 35355 |
| Robert Terkeltaub | 80 | 284 | 21034 |
| Robert M. Graham | 69 | 319 | 16342 |
| Sunil Gupta | 69 | 440 | 33856 |
| Anne Keogh | 64 | 337 | 20268 |
| Filip K. Knop | 61 | 437 | 13614 |
| Peter S. Macdonald | 57 | 455 | 12988 |
| Boris Martinac | 56 | 245 | 14121 |
| Carolyn L. Geczy | 55 | 187 | 8987 |
| Christopher J. Ormandy | 54 | 131 | 8757 |